Overview

NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers

Status:
NOT_YET_RECRUITING

Trial end date:
2026-12-31

Target enrollment:

Participant gender:

Summary

This study will evaluate the safety and efficacy of NALIRIFOX per NAPOLI-3 regimen as first-line chemotherapy for patients with advanced small intestine and appendiceal cancers. Female or male patients aged 18 years, or older, with histopathologically or cytologically confirmed advanced mucinous or non-mucinous appendix cancer or advanced small intestine cancer will be eligible for participation in the study.

Phase:

PHASE1

Details

Lead Sponsor:

The Methodist Hospital Research Institute

Treatments:

Fluorouracil
irinotecan sucrosofate
Oxaliplatin